Literature DB >> 6305841

Separation and purification of the hemagglutinins from Bordetella pertussis.

Y Sato, J L Cowell, H Sato, D G Burstyn, C R Manclark.   

Abstract

The role of the filamentous hemagglutinin (FHA) and the lymphocytosis-promoting factor hemagglutinin (LPF) in pertussis pathogenesis and immunity is the subject of active investigation. To be certain of their role as protective antigens, the hemagglutinins must be pure and free of each other. This report describes procedures to separate and purify FHA and LPF from the culture supernatant of stationary cultures of Bordetella pertussis Tohama, using hydroxylapatite, haptoglobin-Sepharose, and Sepharose CL-6B filtration chromatography. Purified FHA contained less than 0.002% active LPF assayed by histamine-sensitizing activity, and both hemagglutinins contained less than 0.01% of each other based on antigenic activity measured by an enzyme-linked immunosorbent assay, using affinity chromatography-purified antibody to each hemagglutinin. LPF and FHA were also shown to be antigenically distinct by immunodiffusion and were judged to be highly purified proteins by polyacrylamide gel electrophoresis. In addition, the purification procedures yielded milligram amounts of each hemagglutinin with very good recovery of starting activities.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305841      PMCID: PMC264780          DOI: 10.1128/iai.41.1.313-320.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Biological properties of islets-activating protein (IAP) purified from the culture medium of Bordetella pertussis.

Authors:  M Yajima; K Hosoda; Y Kanbayashi; T Nakamura; I Takahashi; M Ui
Journal:  J Biochem       Date:  1978-01       Impact factor: 3.387

2.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

3.  Size and charge isomer separation and estimation of molecular weights of proteins by disc gel electrophoresis.

Authors:  J L Hedrick; A J Smith
Journal:  Arch Biochem Biophys       Date:  1968-07       Impact factor: 4.013

4.  Crystallization of pertussigen from Bordetella pertussis.

Authors:  H Arai; J J Munoz
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

5.  Simple charring method for determination of lipids.

Authors:  J B Marsh; D B Weinstein
Journal:  J Lipid Res       Date:  1966-07       Impact factor: 5.922

6.  Selective breeding to establish a standard mouse for pertussis vaccine bioassay. II. Bioresponses of mice susceptible and resistant to sensitization by pertussis vaccine HSF.

Authors:  C R Manclark; C T Hansen; P E Treadwell; M Pittman
Journal:  J Biol Stand       Date:  1975

7.  A sandwich method of enzymoimmunoassay. I. Application to rat and human alpha-fetoprotein.

Authors:  R Maiolini; R Masseyeff
Journal:  J Immunol Methods       Date:  1975-09       Impact factor: 2.303

8.  Soluble adenylate cyclase from the culture medium of Bordetella pertussis: purification and characterization.

Authors:  E Hewlett; J Wolff
Journal:  J Bacteriol       Date:  1976-08       Impact factor: 3.490

9.  Leukocytosis-promoting factor of Bordetella pertussis. 3. Its identity with protective antigen.

Authors:  Y Sato; H Arai; K Suzuki
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

10.  Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.

Authors:  J J Munoz; H Arai; R L Cole
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

View more
  57 in total

1.  Uptake and intracellular survival of Bordetella pertussis in human macrophages.

Authors:  R L Friedman; K Nordensson; L Wilson; E T Akporiaye; D E Yocum
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

2.  Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.

Authors:  I Marsili; M Pizza; F Giovannoni; G Volpini; M Bartalini; R Olivieri; R Rappuoli; L Nencioni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Characterization of vir-activated TnphoA gene fusions in Bordetella pertussis.

Authors:  T M Finn; R Shahin; J J Mekalanos
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

4.  Properties of the B oligomer of pertussis toxin.

Authors:  L Nencioni; M G Pizza; G Volpini; M T De Magistris; F Giovannoni; R Rappuoli
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

5.  Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis.

Authors:  C A Guzmán; R M Brownlie; J Kadurugamuwa; M J Walker; K N Timmis
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

Review 6.  Pertussis: the disease and new diagnostic methods.

Authors:  R L Friedman
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

7.  Monoclonal antibody-based sandwich enzyme-linked immunosorbent assay for detection of Bordetella pertussis filamentous hemagglutinin.

Authors:  B Gustafsson; P Askelöf
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

8.  Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis.

Authors:  S A Halperin; R Bortolussi; A J Wort
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

9.  Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health laboratories.

Authors:  K H Wong; S K Skelton
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

10.  In vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor.

Authors:  B D Meade; P D Kind; J B Ewell; P P McGrath; C R Manclark
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.